143 related articles for article (PubMed ID: 12429477)
21. Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice.
Cocchietto M; Sava G
Pharmacol Toxicol; 2000 Nov; 87(5):193-7. PubMed ID: 11129497
[TBL] [Abstract][Full Text] [Related]
22. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
[TBL] [Abstract][Full Text] [Related]
23. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.
Groessl M; Zava O; Dyson PJ
Metallomics; 2011 Jun; 3(6):591-9. PubMed ID: 21399784
[TBL] [Abstract][Full Text] [Related]
24. Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme.
Messori L; Merlino A
Dalton Trans; 2014 Apr; 43(16):6128-31. PubMed ID: 24553967
[TBL] [Abstract][Full Text] [Related]
25. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin.
Webb MI; Walsby CJ
Dalton Trans; 2011 Feb; 40(6):1322-31. PubMed ID: 21210063
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
27. Aquation of the ruthenium-based anticancer drug NAMI-A: a density functional study.
Besker N; Coletti C; Marrone A; Re N
J Phys Chem B; 2008 Apr; 112(13):3871-5. PubMed ID: 18331025
[TBL] [Abstract][Full Text] [Related]
28. A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin.
Messori L; Orioli P; Vullo D; Alessio E; Iengo E
Eur J Biochem; 2000 Feb; 267(4):1206-13. PubMed ID: 10672032
[TBL] [Abstract][Full Text] [Related]
29. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
Liu M; Lim ZJ; Gwee YY; Levina A; Lay PA
Angew Chem Int Ed Engl; 2010 Feb; 49(9):1661-4. PubMed ID: 20127775
[No Abstract] [Full Text] [Related]
30. Ruthenium complexes can target determinants of tumour malignancy.
Bergamo A; Sava G
Dalton Trans; 2007 Apr; (13):1267-72. PubMed ID: 17372640
[TBL] [Abstract][Full Text] [Related]
31. Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.
Casini A; Mastrobuoni G; Terenghi M; Gabbiani C; Monzani E; Moneti G; Casella L; Messori L
J Biol Inorg Chem; 2007 Nov; 12(8):1107-17. PubMed ID: 17680283
[TBL] [Abstract][Full Text] [Related]
32. Quantum Chemical Studies on Detail Mechanism of Nitrosylation of NAMI-A-HSA Adduct.
Das D; Mondal P
J Phys Chem B; 2015 Aug; 119(33):10456-65. PubMed ID: 26151453
[TBL] [Abstract][Full Text] [Related]
33. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA
Dwyer BG; Johnson E; Cazares E; McFarlane Holman KL; Kirk SR
J Inorg Biochem; 2018 May; 182():177-183. PubMed ID: 29501978
[TBL] [Abstract][Full Text] [Related]
34. Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.
Mu C; Chang SW; Prosser KE; Leung AW; Santacruz S; Jang T; Thompson JR; Yapp DT; Warren JJ; Bally MB; Beischlag TV; Walsby CJ
Inorg Chem; 2016 Jan; 55(1):177-90. PubMed ID: 26652771
[TBL] [Abstract][Full Text] [Related]
35. NAMI-A preferentially reacts with the Sp1 protein: understanding the anti-metastasis effect of the drug.
Yuan S; Chen S; Wu H; Jiang H; Zheng S; Zhang Q; Liu Y
Chem Commun (Camb); 2020 Jan; 56(9):1397-1400. PubMed ID: 31912815
[TBL] [Abstract][Full Text] [Related]
36. A theoretical study on the hydrolysis process of the antimetastatic ruthenium(III) complex NAMI-A.
Chen J; Chen L; Liao S; Zheng K; Ji L
J Phys Chem B; 2007 Jul; 111(27):7862-9. PubMed ID: 17579393
[TBL] [Abstract][Full Text] [Related]
37. Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244).
Vries JD; Doppenberg WG; Henrar RE; Bult A; Beijnen JH
J Pharm Sci; 1996 Nov; 85(11):1227-33. PubMed ID: 8923330
[TBL] [Abstract][Full Text] [Related]
38. Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.
Bergamo A; Zorzet S; Cocchietto M; Carotenuto ME; Magnarin M; Sava G
Anticancer Res; 2001; 21(3B):1893-8. PubMed ID: 11497274
[TBL] [Abstract][Full Text] [Related]
39. Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry.
Brouwers EE; Tibben MM; Rosing H; Schellens JH; Beijnen JH
Rapid Commun Mass Spectrom; 2007; 21(9):1521-30. PubMed ID: 17410551
[TBL] [Abstract][Full Text] [Related]
40. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
